LiverPro™ - Clinical Trials
|I Product Info||I Ingredients
||I Recommended Use
||I Clinical Trials
||I Research Brief
Indication: liver function protection against toxic substances, inflammatory and degenerative processes in the liver, taking medication (especially antibiotics), alcohol consumption and smoking.
Actions: normalizes liver function, powerful hepatoprotector, promotes anti-inflammatory effect, contains antioxidants, protects liver cells against free radical damage, essential after taking medication (especially antibiotics and paracetamol containing medicine).Ingredients (per one capsule):
SILIPHOS® (Milk Thistle Phytosome® - silybin (from Silybum Marianum L. Gaertn.) phosphatidylcholine complex) (contains 40 mg sylibin, 80 mg phosphatidylcholine) –120 mg.
Low USA domestic & international
LiverPro™ - Clinical Trials:
Clinical studies have been performed to evaluate the properties of SILIPHOS® in subjects with impairment of liver function.
Vailati et al performed an open randomized trial on 65 patients suffering from chronic persistent hepatitis. The protective effects of SILIPHOS® increased with the dose and 240 mg/die p.o. (as silybin) resulted to be the mean therapeutic dose whereas 360 mg/die p.o. (as silybin) was recommended for the treatment of the severe resistant form of hepatitis or during the initial management of the patients. (5)
In a study carried out on 232 patients with alcoholic, acute viral or iatrogenic hepatitis, the subjects have been treated with 240 or 360 mg/die p.o. (as silybin) for 120 days. No side effects have been observed and SILIPHOS®, in comparison with placebo, showed its ability to improve liver condition. (6)
In a short-term pilot study performed on 20 patients with chronic active hepatitis, the biochemical parameters related to hepatocellular damage and necrosis were significantly reduced after 7 days of treatment with 240 mg/die p.o. (as silybin). (Fig. 1) (7)
A 2-month study on 8 patients complaining of chronic active hepatitis has shown the ability of SILIPHOS® to reduce serum MDA concentration and to increase galactose elimination by the liver. (8)
A total of 18 cases of Amanita phalloides poisoning was treated by combined chemotherapy during 1980 and 1981. After attempted primary elimination of the toxin all patients received silybin as basic therapy mainly by infusion and, in two instances, silymarin orally. In order to investigate the effect of silybin therapy a retrospective study of the followed-up case records was made. The cases were arbitrarily classified into three groups of severity (light, medium and severe) according to clinical and laboratory findings. A close relationship was found between the severity of the intoxication and the time elapsed before commencement of silybin therapy. The time interval between mushroom intake and the commencement of the silybin administration averaged 71.5 hours in the "severe" group compared with 46 and 33.8 hours, respectively, in the "medium" and "light" groups. The mean silybin dosage was 33 mg/kg body weight/day; the mean duration of silybin therapy was 81.6 hours. With the exception of one fatality in a particularly high dosage suicidal intoxication, all patients survived.
Administration of silybin within about 48 hours after mushroom intake seems to be an effective measure to prevent severe liver damage in Amanita phalloides poisoning.